Equity Profile

PAHC

Phibro Animal Health Corporation

Health CarePharmaceuticals$1.3B

Aug26Wed

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

Phibro Animal Health Corporation (PAHC) operates in the health care sector, focusing on pharmaceuticals for livestock and pets. The company plays a crucial role in animal health, providing products that enhance animal well-being and productivity, which is increasingly important as global demand for animal protein rises.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $0.76.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PAHC Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q3-2026, Phibro reported an EPS of $0.76, exceeding expectations by 5.85%. The stock reacted positively, gaining 4.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Phibro's upcoming earnings are mixed, with some investors optimistic about continued EPS growth based on past performance.

Bull Case

If Phibro continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $0.76.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for long-term success.

Gross Margin

Not available.

Gross margin indicates how efficiently the company is producing its products and can signal potential profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q4-2026?

Given the company's history of beating EPS estimates, this figure will be crucial for investor sentiment and stock performance.

How has revenue growth trended in the last quarter?

Understanding revenue trends will help gauge the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Phibro's ability to sustain its EPS growth given recent operational efficiencies and market demand for animal health products.

Supporting Evidence

Phibro has consistently beaten EPS estimates, indicating strong management and operational performance.

The options market is pricing in a significant move, suggesting that traders expect a notable reaction based on the earnings report.

Key Risk

If the EPS comes in below $0.70, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining the company's growth trajectory and investor sentiment.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±22.04%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±22.0% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

100.6%

Calls (100)P/C Ratio: 0.14Puts (600)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.4M

42,240 sh

1 insider

Net

$2.4M

Net selling

Most Active Insiders· 12 open-market trades

President and CEOBENDHEIM JACK
$2.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats expectations, history suggests a potential stock increase of around 0.37%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.28%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansions.
2Insights into cost management strategies and their impact on gross margins.
3Comments on competitive pressures in the animal health market.
4Guidance on revenue expectations for the upcoming quarters.
5Management's outlook on global demand for animal health products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Sandisk Corporation

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $0.76.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PAHC Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q3-2026, Phibro reported an EPS of $0.76, exceeding expectations by 5.85%. The stock reacted positively, gaining 4.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Phibro's upcoming earnings are mixed, with some investors optimistic about continued EPS growth based on past performance.

Bull Case

If Phibro continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $0.76.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for long-term success.

Gross Margin

Not available.

Gross margin indicates how efficiently the company is producing its products and can signal potential profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q4-2026?

Given the company's history of beating EPS estimates, this figure will be crucial for investor sentiment and stock performance.

How has revenue growth trended in the last quarter?

Understanding revenue trends will help gauge the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Phibro's ability to sustain its EPS growth given recent operational efficiencies and market demand for animal health products.

Supporting Evidence

Phibro has consistently beaten EPS estimates, indicating strong management and operational performance.

The options market is pricing in a significant move, suggesting that traders expect a notable reaction based on the earnings report.

Key Risk

If the EPS comes in below $0.70, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining the company's growth trajectory and investor sentiment.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±22.04%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±22.0% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

100.6%

Calls (100)P/C Ratio: 0.14Puts (600)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.4M

42,240 sh

1 insider

Net

$2.4M

Net selling

Most Active Insiders· 12 open-market trades

President and CEOBENDHEIM JACK
$2.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats expectations, history suggests a potential stock increase of around 0.37%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.28%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansions.
2Insights into cost management strategies and their impact on gross margins.
3Comments on competitive pressures in the animal health market.
4Guidance on revenue expectations for the upcoming quarters.
5Management's outlook on global demand for animal health products.